GSK-251154

GSK-251154 is an experimental, reduced-antigen-content tri-component acellular pertussis (pa) vaccine developed by GSK. It is specifically designed for administration as a birth dose to neonates to provide early protection against *Bordetella pertussis* before the standard primary pediatric vaccination series begins. The vaccine formulation consists of three purified antigens: pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (PRN). The reduced antigen concentration is intended to minimize reactogenicity and the potential for immune interference with subsequent vaccinations while successfully priming the infant's immune system. Clinical development has focused on evaluating its safety and immunogenicity when followed by routine hexavalent or pentavalent pediatric vaccines.

Other names

Reduced-antigen-content tri-component pertussis vaccineGSK acellular pertussis vaccinepa vaccineTri-component pertussis vaccine